KDIGO: Anticoagulation Considerations in Chronic Kidney Disease

Launch Date

12/22/2023

Credit Amount

0.00 Resources

Credit Expires

This activity is part of a series

Direct Oral Anticoagulants (DOACs) have come of age and are proving to be an efficacious and convenient means to provide anticoagulation for many patients with NVAF and/or VTE. However, striking the right balance between anticoagulation and bleeding risk is paramount, especially for patients with chronic kidney disease. This resource, adapted from the KDIGO (Kidney Disease Improving Global Outcomes) guidelines, provides a quick reference to warfarin and DOAC dosing, including adjustments for creatinine clearance (CrCl) in patients with various levels of renal insufficiency.